Best Warren Buffett Stocks To Buy Right Now


Billionaire investor Warren Buffett was a sharp critic of Donald Trump during the presidential campaign, but said in an interview broadcast by CNN Friday that he expects the stock market to continue rising.

The stock market will be higher 10, 20 and 30 years from now and it would have been with Hillary [Clinton] and it will be with Trump, Buffett said. Suggestions by market pundits that stocks would plunge after a Trump victory were silly, he said.

Best Warren Buffett Stocks To Buy Right Now: Royal Dutch Shell PLC(RDS.A)


Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    A number of oil and gas companies have backed the accord as well, including Chevron (CVX) , Royal Dutch Shell (RDS.A) and BP (BP) . Exxon (XOM) in March sent a letter to the White House urging it to stay in the Paris agreement, and CEO Darren Woods penned a personal letter to the president addressing the matter, the Financial Times reported last week.

  • [By Money Morning News Team]

    A $2 trillion valuation makes the company worth more than Chevron Corp. (NYSE:CVX), BP Plc. (NYSE ADR:BP), Exxon Mobil Corp. (NYSE: XOM), and Royal Dutch Shell Plc. (NYSE: RDS.A) – combined.

  • [By Dustin Parrett]

    Big Oil stocks are the seven “oil supermajors” that do everything from oil drilling to refining to retail sales. This is a list of the Big Oil companies:

    Big Oil CompanyShare PriceYTDMarket CapExxon Mobil Corp. (NYSE: XOM)$83.44-7.58%$353.13BChevron Co. (NYSE: CVX)$113.56-3.5%$217.62BConocoPhillips Co. (NYSE: COP)$48.21-3.78%$61.42BRoyal Dutch Shell Plc. (NYSE ADR: RDS.A)$52.35-3.82%$221.08BBP Plc. (NYSE ADR: BP)$34.12-8.71%$112.69BTotal SA (NYSE: TOT)$50.26-1.35%$124.6BEni SpA (NYSE: E)$31.51-2.3%$58.69B


    Despite being huge global oil companies, shares of Big Oil stocks are all in the red this year. Those losses have all happened even as the Dow is smashing record highs and trading up 6.4% year to date.

  • [By WWW.THESTREET.COM]

    Global oil prices nudged higher Monday even amid reports that Royal Dutch Shell (RDS.A) is re-starting a key Houston refinery that was shuttered by Hurricane Harvey three weeks ago.

Best Warren Buffett Stocks To Buy Right Now: The NeutriSci International (NU)


Advisors’ Opinion:

  • [By Bryan Murphy]

    In the grand scheme of things it shouldn’t be surprising, though odds are good at least a few people are surprised at how quickly it happened. That is, health supplement and healthy-foods brand name NeutriSci International Inc (CVE:NU) and the developer of a cannabis-infusion technology — a means of packing more CBD into hemp oil — called Lexaria Bioscience Corp (OTCMKTS:LXRP) have finalized new supplement that is done testing and will soon be available for consumers. The tablet (a ‘melt’, technically) is a combination of pterostilbene and cannabidiol, offering a double-barreled benefit to the health-conscious.


    The benefits of cannabidiol, found in hemp and marijuana, are relatively well understood by the market at this point. Cannabidiol can do a human body a lot of good, like the reduction of nausea, control of seizures, anti-cancer activity, anti-inflammation effects, and more. Pterostilbene is the lesser-known of the two components of the new tablet, but no less impressive and no less beneficial. Pterostilbene is known to combat high cholesterol, high blood pressure, and oxidative stress. Combining the two is a real one-two punch for the health-conscious.

    That’s what made November’s news so exciting… NeutriSci International has an established name and marketing channel, while Lexaria Bioscience has the science that makes hemp oil far more functional. Indeed, to fully appreciate the upside for LXRP, one has to embrace Lexaria’s science and why it matters.


    The bulk of the vitamins, anti-oxidants, minerals, amino acids and all the other desirable components of the pills you take and foods you eat don’t actually get absorbed into your body. Sometimes as much as 96% of the ingredient in question isn’t extracted, and instead passes right through. Not only is it a waste of time and money, it’s a bit of a hassle to swallow a big capsule — or several capsules — for little to no benefit.

    Lexaria Bioscience changes this. In short,

  • [By Matthew Briar]

    What do you get when you cross a science that drastically improves the absorption of cannabidiol (the healthy component of cannabis) with pterostilbene (an antioxidant) tablet? It’s not a joke in search of a punch line. It’s going to be the health supplement millions of consumers have been waiting for, brought to them by a joint venture between NeutriSci International Inc (CVE:NU) and Lexaria Bioscience Corp (OTCMKTS:LXRP). The two companies announced this morning they were entering a joint venture that would utilize Lexaria Bioscience’s proprietary infusion platform and tap into NeutriSci International’s existing distribution network to create and market a whole new supplement product line.


    Lexaria has developed and patented a technology that makes valuable molecules taste better and absorb better in the digestive tract. This platform could be applied to a variety of nutritional and health-oriented favorites, but Lexaria is starting with hemp as it’s the most underserved market and arguably the biggest growth opportunity.

    Just to be clear, hemp and marijuana are not the same thing. Hemp doesn’t have any tetrahydrocannabinol (or THC) in it, which is the key driver of its psychoactive — the ‘high’ — response. Hemp, and hemp oil to be exact, does have cannabidiol in it though, and for those who’ve been following the saga of medical marijuana and cannabis, they’ll know cannabidiol can provide a lot of various medical benefits like the reduction of nausea, control of seizures, anti-cancer activity, anti-inflammation effects, and more.


    NeutriSci International is Canadian corporation that specializes in the marketing, development and distribution of proprietary nutraceuticals. It’s got a rather wide array of products in its portfolio, but the one of immediate interest is its pterostilbene, as it fits best with the hemp-absorption technology Lexaria Bioscience brings to the table.

    Pterostilbene (found in blueberries, by the way) is o

  • [By Matthew Briar]

    Last week — to the day, in fact — Lexaria Bioscience Corp (OTCMKTS:LXRP) announced it was teaming up with neutraceutical company NeutriSci International Inc (CVE:NU) to create a new kind of health supplement that gave consumers the ability to tap into the benefits of hemp. We hailed it as the shape of things to come. What we didn’t know, however, was how quickly those things would take shape. Just this morning the company told LXRP shareholders it was already forging another such symbiotic relationship…. this one with Hempco Food and Fiber Inc (CVE:HEMP).


    Simply put, Lexaria Bioscience is focused on improving the bioavailability of the healthy stuff found in food, supplements, vitamins, and yes, even in cannabis and hemp.

    It’s not widely recognized, but the bulk of the vitamins, anti-oxidants, minerals, amino acids and all the other desirable components of the pills you take and foods you eat don’t actually get absorbed into your body. Sometimes as much as 96% of the ingredient in question isn’t extracted, and instead passes right through. Not only is it a waste of time and money, it’s a bit of a hassle to swallow a big capsule — or several capsules — for little to no benefit.


    Lexaria Bioscience changes this. In short, Lexaria has developed and patented a proprietary technology that makes valuable molecules taste better and absorb better in the digestive tract. This platform could be applied to a variety of nutritional and health-oriented favorites, but Lexaria is starting with hemp as it’s the most underserved market and arguably the biggest growth opportunity. Hemp, and hemp oil to be exact, can provide a lot of various medical benefits like the reduction of nausea, control of seizures, anti-cancer activity, anti-inflammation effects, and more.


    The future for Lexaria Bioscience is partnerships… licensing its science and know-how to companies with existing product lines and distribution networks that can easily inject hemp

  • [By Matthew Briar]

    Indeed, it’s also garnered interest from business partners. In November, Lexaria Bioscience and NeutriSci International Inc (CVE:NU) jointly announced they were entering a joint venture that would utilize Lexaria Bioscience’s proprietary infusion platform and tap into NeutriSci International’s existing distribution network to create and market a whole new supplement product line. In January, the duo announced it had finalized new supplement that is done testing and will soon be available for consumers. The tablet (a ‘melt’, technically) is a combination of pterostilbene and cannabidiol, offering a double-barreled benefit to the health-conscious.

Best Warren Buffett Stocks To Buy Right Now: Great Canadian Gaming Corporation (GCGMF)


Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    SA: You recently published a thesis on Great Canadian Gaming (OTCPK:GCGMF), a Canadian company do you see the Canadian (or another) market as having greater opportunity to uncover hidden value than the U.S.?

Best Warren Buffett Stocks To Buy Right Now: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Biogen (BIIB) has dropped 2.2% to $286.16 after getting cut to Market Perform from Outperform at Leerink, and to Equal Weight from Overweight at Morgan Stanley.

  • [By WWW.THESTREET.COM]

    Breakups have the potential to create a lot of value. Just look at what Biogen (BIIB) did with its hemophilia franchise. Spun out as Bioverativ (BIVV) , shares started trading earlier this year. The stock has climbed some 23% on seemingly no news, Cramer noted.

  • [By Chris Lange]

    Biogen Inc. (NASDAQ: BIIB) had its short interest increase to 2.63 million shares from the previous 2.36 million. The stock closed Friday at $305.20, within a 52-week range of $223.02 to $333.65.

  • [By WWW.MONEYSHOW.COM]

    Biogen (BIIB)

    Biogen discovers, develops and delivers innovative therapies for the treatment of neurodegenerative diseases and autoimmune disorders.

Best Warren Buffett Stocks To Buy Right Now: Avid Technology Inc.(AVID)


Advisors’ Opinion:

  • [By Monica Gerson]

    Avid Technology, Inc. (NASDAQ: AVID) is estimated to post its quarterly earnings at $0.36 per share on revenue of $144.02 million.

    Consolidated Water Co. Ltd. (NASDAQ: CWCO) is expected to post its quarterly earnings at $0.11 per share on revenue of $15.15 million.

  • [By Anders Bylund]

    Shares of Avid Technology(NASDAQ:AVID) rose 20.3% in April 2017, according to data from S&P Global Market Intelligence.


    So what

    Last month’s share price surge rested on Avid’s release of a coherent cloud-based media production suite. The new version of Avid’s MediaCentral platform takes advantage of the cloud, central storage, and back-end data processing in a way older versions never attempted, modernizing the media production tool in a big way.

  • [By Lisa Levin]

    Avid Technology, Inc. (NASDAQ: AVID) shares were also up, gaining 24 percent to $5.01 following Q3 results. Avid Technology reported Q3 earnings of $0.00 per share on revenue of $105.26 million.

Best Warren Buffett Stocks To Buy Right Now: Coca-Cola Company (The)(KO)


Advisors’ Opinion:

  • [By Chris Lange]

    The Coca-Cola Co. (NYSE: KO) will share its latest quarterly earnings on Wednesday. The consensus estimates call for $0.58 in EPS and $9.65 billion in revenue. Shares ended last week at $45.03, in a 52-week range of $39.88 to $46.06. The consensus price target is $45.68.

  • [By Jayson Derrick]

    The Coca-Cola Co (NYSE: KO)’s bottom half of 2017 will be led by its new CEO James Quincey while the company will show “clearer evidence” of margin improvements and earnings per share upside as bottler re-franchising deals close.

  • [By WWW.THESTREET.COM]

    Originally published Nov. 17 at 3:41 p.m. EDT

    The consideration of the contrary has been a theme all week. And here in ” Don’t Run With the Crowd: Embrace the Contrary.”   Miami madness (of a real estate kind)   Mark Grant is scared by our currency’s strength.   Danielle on scenarios.   Boockvar to subscriber Bad Golfer!   JC Penney ( JCP) short puts–a 100% win. (Shorting options frequently ends differently!)   Just say no to closed-end muni-bond funds.   DRYS is all wet.   Could iPhone manufacturing be coming back home?   On inflation breakevens–a picture that speaks volumes.   The market moved higher from the “get go”–in large measure it seems to be a response to the better economic data this morning.   At 3 p.m. stocks were near the day’s highs.   I shorted The Cisco Kid last night. Sticking with this short rental. I added to my ProShares UltraShort S&P500 ETF ( SDS) long (growing ever larger). My net short exposure–is now between small and medium-sized at the close. The U.S. dollar, as discussed above, continued to rip higher against the euro. I am concerned. Mark Grant is concerned. The market is not concerned. The price of crude oil (down $0.20) settled lower after yesterday’s robust gains. Gold fell $9 as it continues to break down–closing in on $1,200. Ag commodities: wheat up $0.07, corn up $0.04, soybeans up $0.05 and oats up $0.02. Lumber up $7 following the big housing number this morning. Bonds schmeissed … iShares Barclays 2

  • [By The Ticker Tape]

    For more earnings coverage, check out what might be expected when McDonald's Corporation (NYSE: MCD) The Coca-Cola Co (NYSE: KO), and Chipotle Mexican Grill, Inc. (NYSE: CMG) report earnings tomorrow. Later in the week, tech titans Amazon.com, Inc. (NASDAQ: AMZN), Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGL), Microsoft Corporation (NASDAQ: MSFT) and Intel Corporation (NASDAQ: INTC) report after market close on Thursday.

  • [By Ben Levisohn]

    We recently reached out to our retailer contacts to get an updated read on recent performance of Monster. Based on retailer feedback, we see a negative risk/reward for the stock ahead of Q4 results on 3/1 given: (1) soft scanner data, particularly in Dec & Jan as energy sales are definitely soft compared to other categories according to one retailer while another reported Monster started 2017 off horribly; (2) Java production issues persist; (3) poor retailer feedback on the rollout of Mutant continues in part based on the view that Coca-Cola (KO) is not executing on all cylinders and consumer reception of the product has not shown it to be anything great and certainly at this point is no threat to Mt. Dew; and (4) retailers modest outlook for Monster in 2017 (low- to mid-single digit growth on average).